CIMTEC Client 3D Signatures Advances Hodgkin’s Lymphoma Test

TORONTO, ON − 3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the “Company” or “3DS”), is pleased to announce that the clinical trial component (the “Clinical Trial”) of its Hodgkin’s lymphoma (“HL”) test (“Telo-HL”) validation program is successfully underway. This process is referred to as Stage 3 of the validation program as set out in the Company’s news release dated February 23, 2017. Assay development and assay validation, Stage 1 and Stage 2 of the validation program, respectively, were completed on schedule. The Clinical Trial is expected to be complete by Sept 30, 2017.